SynthesisThe Cochrane database of systematic reviews2009
Haemostatic drug therapies for acute spontaneous intracerebral haemorrhage.
Synthesis in The Cochrane database of systematic reviews, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 6 syntheses or guidelines pooled it, 74 citations in OpenAlex.
- Haemostatic therapies for stroke due to acute, spontaneous intracerebral haemorrhage.The Cochrane database of systematic reviews · 2023Pooled it
- Haemostatic therapies for acute spontaneous intracerebral haemorrhage.The Cochrane database of systematic reviews · 2018Pooled it
- Pooled it
- Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications.Annals of internal medicine · 2011Pooled it
- Edaravone for acute intracerebral haemorrhage.The Cochrane database of systematic reviews · 2011Pooled it
- Use of recombinant factor VIIa for the prevention and treatment of bleeding in patients without hemophilia: a systematic review and meta-analysis.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2011Pooled it
- Management of Spontaneous Intracerebral Hematoma.Neurologia medico-chirurgica · 2017Review
- Management of Spontaneous Intracerebral Hemorrhage.Current neurology and neuroscience reports · 2017Review
- Management of acute intracerebral haemorrhage - an update.Clinical medicine (London, England) · 2017Article
- Treatment of intracerebral haemorrhage with tranexamic acid - A review of current evidence and ongoing trials.European stroke journal · 2017Review
- Prothrombin Complex Concentrates for Bleeding in the Perioperative Setting.Anesthesia and analgesia · 2016Review
- Progressing haemorrhagic stroke: categories, causes, mechanisms and managements.Journal of neurology · 2014Review
- Intracranial hemorrhage and novel anticoagulants for atrial fibrillation: what have we learned?Current cardiology reports · 2014Review
- [Intracranial hemorrhage: diagnosis, prognosis, acute treatment and secondary prophylaxis].Der Nervenarzt · 2012Review
- Hemorrhagic progression of a contusion after traumatic brain injury: a review.Journal of neurotrauma · 2012Review
- Postoperative intracranial haemorrhage: a review.Neurosurgical review · 2011Review
- European research priorities for intracerebral haemorrhage.Cerebrovascular diseases (Basel, Switzerland) · 2011Review
- The persisting burden of intracerebral haemorrhage: can effective treatments be found?PLoS medicine · 2010Review
- Spontaneous intracerebral and intraventricular hemorrhage. Hemostasis by transarterial glue embolization.Clinical neuroradiology · 2010Article
Corrections and comments
- Updated by
- Update of
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBecause spontaneous (non-traumatic) intracerebral haemorrhage (ICH) volume influences its outcome and a third of ICHs enlarge by a third within 24 hours of onset, early haemostatic drug therapy might improve outcome. This is an update of a Cochrane review first published in 2006.
objectivesTo examine the clinical effectiveness and safety of haemostatic drug therapies for acute ICH in a randomised controlled trial (RCT) design. SEARCH STRATEGY: I searched the Cochrane Stroke Group Trials Register (last searched 26 June 2009), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 2, 2009), MEDLINE (1966 to June 2009) and EMBASE (1980 to June 2009). In an effort to identify further published, ongoing and unpublished studies I scanned bibliographies of relevant articles, searched international registers of clinical trials and research, and contacted authors and pharmaceutical companies. SELECTION CRITERIA: I sought RCTs of any haemostatic drug therapy for acute ICH, compared against placebo or open control, with relevant clinical outcome measures. DATA COLLECTION AND ANALYSIS: Two authors independently applied the inclusion criteria, reviewed the relevant studies, and extracted data. MAIN
resultsI found five phase II RCTs and one phase III RCT, involving 1398 adults aged 18 years or over, within four hours of ICH onset: 423 participants received placebo and 975 participants received haemostatic drugs (two received epsilon-aminocaproic acid (EACA) and 973 received recombinant activated factor VII (rFVIIa)). Haemostatic drugs did not significantly reduce 90-day case fatality after ICH (risk ratio (RR) 0.85, 95% confidence interval (CI) 0.58 to 1.25), and rFVIIa did not significantly reduce death or dependence on the modified Rankin Scale (grades 4 to 6) within 90 days of ICH (RR 0.91, 95% CI 0.72 to 1.15). There was a trend towards more participants on rFVIIa experiencing thromboembolic serious adverse events (RR 1.37, 95% CI 0.74 to 2.55) AUTHORS'
conclusionsHaemostatic drugs cannot be recommended for the treatment of acute spontaneous ICH in clinical practice, but a large RCT would be justified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.